CIC
NTLA icon

Carnegie Investment Counsel’s Intellia Therapeutics NTLA Stock Holding History

Carnegie Investment Counsel’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-35,000
Closed -$467K – 433
2019
Q3 		$467K Sell
35,000
-25,000
-42% -$399K 0.03% 302
2019
Q2 		$982K Buy
+60,000
New +$943K 0.06% 219

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Carnegie Investment Counsel's NTLA Position: Q4 2019 in Review

Carnegie Investment Counsel sold out of Intellia Therapeutics (NTLA) in Q4 2019, closing a stake of 35,000 shares — an estimated $467K sold.

Carnegie Investment Counsel first reported a position in NTLA in Q2 2019 and held it in 2 quarters. The position peaked at $982K in Q2 2019. 143 funds tracked by Wall St. Rank hold NTLA as of Q4 2019.

  • Carnegie Investment Counsel reported no remaining Intellia Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Carnegie Investment Counsel sold 35,000 Intellia Therapeutics shares in Q4 2019, an estimated $467K.
  • Carnegie Investment Counsel first reported a position in Intellia Therapeutics in Q2 2019 and held it in 2 quarters.
  • Carnegie Investment Counsel's Intellia Therapeutics position peaked at $982K in Q2 2019.
  • 143 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2019.

Based on Carnegie Investment Counsel's 13F filing for Q4 2019, filed 13 Feb 2020.